NXTC NextCure, Inc.
Price Chart
Executive Summary
NextCure presented Phase 1 dose escalation data for its CDH6-targeting ADC, SIM0505, at ASCO 2026, showing a 55% ORR in gynecologic cancers (52.9% ovarian, 66.7% USC) at therapeutic doses with a manageable safety profile. The company also updated its cash runway guidance, stating existing cash funds operations into Q1 2027. The data is clinically encouraging for a heavily pre-treated population, but the stock has historically not reacted positively to similar neutral-scored filings.
Actionable Insight
The 55% ORR in heavily pre-treated gynecologic cancers is a strong early efficacy signal that differentiates SIM0505 from standard-of-care options (10-25% ORR in PROC). The manageable safety profile supports dose optimization and pivotal trial planning. However, the stock's historical T+20 performance on neutral filings has been negative (-16.16% avg), suggesting limited market enthusiasm for early-stage data. Monitor the June 2 KOL event and upcoming dose optimization update in Q1 2027 for further catalysts.
Key Facts
- Phase 1 dose escalation data for SIM0505 (CDH6 ADC) showed 55% ORR (11/20) in gynecologic cancers at 4.8-8.0 mg/kg with ≥12 weeks follow-up.
- Ovarian cancer ORR was 52.9% (9/17); USC ORR was 66.7% (2/3).
- Safety profile was manageable; Grade 3/4 TEAEs were predominantly hematological; 3 patients discontinued due to TRAEs.
- Company believes existing cash ($29.7M as of March 31, 2026) funds operations into Q1 2027.
- Dose optimization in PROC initiated in May 2026; pivotal trial planning underway.
- FDA granted Fast Track Designation for SIM0505 in PROC.
Financial Impact
No revenue or earnings reported; cash runway of $29.7M into Q1 2027 provides ~9 months of funding at current burn rate.
Risk Factors
- Early-stage data with small sample sizes (n=20 evaluable); ORR may not be durable or replicable in larger trials.
- Cash runway only into Q1 2027; likely need for additional financing before pivotal trial completion.
- Competition from other CDH6 ADCs (e.g., Raludotatug deruxtecan) could limit market opportunity.
- Historical stock performance shows poor follow-through on similar filings, suggesting skepticism from the market.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d1.htm | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d3.htm | 0001104659-26-068604 |
| Document: nxtc-20260601xex99d2.htm | 0001104659-26-068604 |
| Document: 0001104659-26-068604-index-headers.html | 0001104659-26-068604 |
| Document: 0001104659-26-068604-index.html | 0001104659-26-068604 |
| Document: 0001104659-26-068604.txt | 0001104659-26-068604 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $3.38 $3.40 | ▲ +0.59% | ▲ +0.45% | $2.95 (−12.72%) |
|
Jun 1, 2026
4d ago
|
Press Release
| $3.38 $3.40 | ▲ +0.59% | ▲ +0.45% | $2.95 (−12.72%) |
|
May 7, 2026
29d ago
|
8-K
| $9.76 $9.78 | ▲ +0.20% | ▼ −0.03% | $2.95 (−69.77%) |
|
May 4, 2026
4w ago
|
Press Release
| $8.92 $9.32 | ▲ +4.48% | ▲ +3.69% | $2.95 (−66.93%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.62 $9.25 | ▼ −3.85% | ▼ −3.36% | $2.95 (−69.33%) |
|
Apr 21, 2026
6w ago
|
Press Release
| $10.97 $12.00 | ▲ +9.39% | ▲ +8.37% | $2.95 (−73.11%) |
|
Mar 5, 2026
13w ago
|
8-K
| $12.39 $12.51 | ▲ +0.97% | ▲ +0.12% | $2.95 (−76.19%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $12.39 $12.51 | ▲ +0.97% | ▲ +0.12% | $2.95 (−76.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access